Clinical Trial Update: Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating rifaximin SSD tablets to prevent complications in early decompensated liver cirrhosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis

Drugs mentioned

• Rifaximin SSD tablets (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Liver Cirrhosis | Phase 2 | Status: COMPLETED